Continuing the Fight for a Myeloma Cure: Dr. Tricot and Dr. Zhan's Research to Improve Outcomes for High-Risk Myeloma Patients
Guido Tricot, MD, PhD has devotedly attended to thousands of multiple myeloma patients for over two decades. His tandem autologous transplant approach has increased the median survival rate of his patients to 10 years or more, far longer than the national average. In a 20-year research partnership with Dr. Fenghuang (Frank) Zhan, Dr. Tricot and his research team have identified specific genetic types of myeloma, helping to personalize care for each patient's unique kind of myeloma. Their goal now is to leverage that deep expertise to extend life expectancy, overcome drug resistance and prevent myeloma relapse. They are doing this in three ways:
- Using IV Vitamin C with melphalan to reduce transplant toxicities while extending life.
- Targeting a gene called TRIP13 which is heightened even in patients achieving complete response after transplant, in order to reduce myeloma cell growth.
- Shutting down the culprit gene NEK2 which is thought to create instability and promote myeloma cell growth, in order to overcome drug resistance.
While Dr. Tricot is retiring, he is not giving up on the fight against myeloma. In fact he is energized to continue research that will lengthen life for patients. We need your help in supporting the life-saving and groundbreaking work of Dr. Tricot and Dr. Zhan. You can do this by donating below to their University of Iowa myeloma research fund. Please contact the Myeloma Crowd at email@example.com to coordinate major donations. We invite you to donate or become a fundraiser and share this campaign with family, friends and past patients of Dr. Tricot's. Thank you for helping honor his excellence in care to keep this winning team going.